The exofacial part of transmembrane domain 5 (TMD 5) of the cationic amine-binding subclass of 7-transmembrane receptors is thought to be important in binding the side chain of the agonist. Residues Ile-188 through Ala-196 in TMD 5 of the M 1 muscarinic acetylcholine receptor (mAChR) have been studied by Cys-and Ala-scanning mutagenesis. The results are consistent with a helical conformation for this sequence. The positively charged sulfhydryl reagent N-trimethyl-2-aminoethyl methanethiosulfonate reacted selectively with Phe-190 3 Cys, Thr-192 3 Cys, and Ala-193 3 Cys, indicating that the face of TMD 5 accessible from the binding site crevice is consistent with a recent model by Baldwin and colleagues of the transmembrane domain of the 7-transmembrane receptors. In contrast, the acetylcholine derivative bromoacetylcholine reacted selectively with Thr-192 3 Cys, which forms the focus of a group of amino acids whose mutation decreased the binding affinity of the transmitter ACh itself. The center of this patch of residues is offset to one side of the binding pocket, suggesting that a rotation of TMD 5, relative to that implied by the Baldwin model, may be necessary to optimize the anchoring of acetylcholine within the binding site of the M 1 mAChR. An induced rotation of TMD 5 could contribute to the formation of the activated state of the receptor.
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Amino acids located in the exofacial region of the transmembrane domain (TMD) of the cationic amine-binding subclass of G protein-coupled receptors (GPCRs) are important for agonist binding (for review, see Strange, 1996) . Most of the experimental data has come from mutations that reduce the binding affinities of specific ligands. Such information can suggest, but not prove, the existence of a direct receptorligand contact, because indirect conformational effects of mutations on the ligand binding site cannot be excluded (Shortle, 1992; Colquhoun, 1998) .
In TMD 5 of the cationic amine receptors, the sequences that lie near or within the outer leaflet of the phospholipid bilayer typically contain several polar amino acids that vary according to the pharmacology of the receptor. Catecholamine receptors contain two or three serines at positions 5. 42, 5.43, and 5.46 , using the standard nomenclature of Ballesteros and Weinstein (1995) . These participate in the ligation of the catechol m-and p-hydroxyl groups, although the pattern varies according to the receptor type (Strader et al., 1989; Wang et al., 1991; Mansour et al., 1992; Pollock et al., 1992; Cavalli et al., 1996; Hwa and Perez, 1996; Wetzel et al., 1996; Wiens et al., 1998; Sartania and Strange, 1999) . In the 5-HT1A receptor positions may interact with the 5Ј-hydroxyl group, whereas in the 5-HT6 receptor Thr-5.46 may interact with the indole nitrogen of 5-HT (Ho et al., 1992; Boess et al., 1997) . In the histamine H 1 receptors, Asn-5.46 is important for the binding of histamine (Ohta et al., 1999) , whereas position 5.42 is relatively unimportant. In the H 2 receptors, Asp-5.42 and Thr-5.46 have both been suggested to interact with the imidazole ring of histamine (Gantz et al., 1992) .
The muscarinic acetylcholine receptors (mAChRs) contain one threonine at position 5.42, and a second at 5.39, whereas positions 5.43 and 5.46 are occupied by alanines. Positions 5.39 and 5.42 have been investigated in the M 3 mAChR by mutation to alanine (Wess et al., 1991) , in a study in which the mutants were probed with a series of acetylcholine (ACh) analogs, in which various elements of the ACh ester linkage were substituted by methylene groups or by a sulfur atom (Wess et al., 1992) . Position 5.42 has also been examined by alanine substitution in the M 1 mAChR (Huang et al., 1999) . In general, the results supported the conjecture that are important in defining the binding site for the ACh side chain. However, both "productive" and "nonproductive" modes of binding of ACh analogs exist, and replacement of polar by nonpolar moieties within the side chain of ACh can alter the balance between these modes of binding . For this reason, it has not been possible to identify specific interactions between the Thr residues and moieties within the ACh molecule using alanine mutants alone.
In this study, we report an alternative approach. It is based on cysteine substitution of all of the amino acids between ) of the rat M 1 mAChR, followed by chemical reaction of the mutant receptors with a variety of sulfhydryl-directed reagents with reactive side chains. A similar approach has been applied to TMD 5 of the ␣ 2A -adrenergic receptor (Marjamä ki et al., 1998 (Marjamä ki et al., , 1999 .
In addition to positively and negatively charged methanethiosulfonate derivatives (Javitch et al., 1995) , we have used a derivative of ACh, bromoacetylcholine (BrACh), in which halogenation of the acetyl methyl group creates a compound with the potential to alkylate sulfhydryl groups.
The ability of BrACh to block the binding site of the M 1 mAChR was strongly enhanced after the introduction of sulfhydryl groups into TMD 5 by Cys substitution of particular amino acids. Selective blockade of the Thr-192 3 Cys mutant by BrACh suggests that the alkylating side chain of the affinity label can contact position 5.42. Thus, the threonine methyl group at position 192 may be positioned to make a Van der Waals contact with the acetyl methyl group of ACh in the wild-type receptor. Substitution mutagenesis experiments support the view that this residue and its neighbors contribute to a binding pocket for the acetyl methyl group of ACh. This may account for the high affinity and potency of ACh relative to formylcholine. The comparison of functional with binding data suggests that the interactions made by residues in TMD 5 are more important for the binding of ACh than for the induction of the conformational change that leads to phosphoinositide (PI) signaling. Preliminary accounts of some of these experiments have been published (Allman et al., 1997) .
Experimental Procedures
Methods. The experimental procedures were performed as described previously. Briefly, residues 188 through 196 of the rat M 1 mAChR were individually mutated to Cys, Ala, Gly, or Ser (Ala itself was changed to Gly, and Gly to Ala) using a polymerase chain reaction method (Lu et al., 1997) or the Amersham phosphorothioate method . Mutant receptors, cloned into the pCD expression vector, and verified by dideoxy sequencing, were transiently expressed in COS-7 cells following transfection by electroporation. Membrane preparations were made 3 days after transfection Binding of (Ϫ)-N-[ 3 H]methyl scopolamine ([ 3 H]NMS), ACh, and other ligands was measured at 30°C in a buffer containing 20 mM Na-HEPES, 100 mM NaCl, and 1 mM MgCl 2 , pH 7.5, using an incubation time of 60 min . Data analysis was performed using the program Sigma Plot 3.03 (SPSS Inc.). Binding curves were fitted to the Hill equation, or to one-site, two-site, or ternary complex models of binding, and affinity constants were corrected for the Cheng-Prusoff shift, as necessary . PI dose-response curves were fitted to a fourparameter logistic function, yielding EC 50 and E max values. Values of signaling efficacy, adjusted for variations in receptor expression, were calculated as described (Hulme and Lu, 1998; Lu and Hulme, 1999; Ward et al., 1999) .
Expression of receptor protein was assessed by immunocytochemical visualization of transfected cells using an immunoaffinity-purified antiserum raised against the C-terminal 13 amino acids of the sequence, as described (Lu et al., 1997 . Other materials were of the highest commercial grade available.
Results

Binding of [ 3 H]NMS
Of the mutations of Ile-188 through in mutations strongly affected the expression of the receptor or its processing to a form capable of high-affinity antagonist binding. These results were confirmed by immunocytochemical visualization of the expressed protein using an anti-Cterminal antibody (Lu et al., 1997) ; (data not shown).
Binding of ACh
The binding of ACh to the wild-type M 1 receptor expressed in COS-7 cells was characterized by a slightly flattened binding isotherm (n H ϭ 0.88), and a pIC 50 of 4.9. The binding of ACh to the wild-type receptor showed little if any GTP sensitivity in these experiments (data not shown). The effects of the mutations of Ile-188 through Ala-196 are summarized in Fig. 1a . Mutations of four residues, , caused significant reductions in ACh affinity, the largest effects being slightly over 10-fold (Thr-192 3 Cys, Ala-196 3 Cys). Where comparisons could be made, the effects of other mutations at the same positions (Ile-188 3 Ala, Thr-192 3 Ala, and Ala-196 3 Gly) were similar, but slightly smaller.
In contrast, the mutation Phe-190 3 Cys caused a 6-fold increase in ACh affinity, and a reduction in the Hill coefficient (n H ϭ 0.70) (Fig. 2a ). This effect was not seen for the corresponding Ala substitution.
Binding of Other Agonists
The effects of the Cys mutations of on the binding affinities of two other muscarinic agonists of high efficacy, carbachol and oxotremorine-M were qualitatively similar to but quantitatively smaller than their effects on the binding of ACh (carbachol: 3-fold increase at Phe-190 3 Cys, 7-fold reduction at Thr-192 3 Cys, 3-fold reduction at Ala-196 3 Cys; oxotremorine-M: 2-fold increase at Phe-190 3 Cys, 4-fold reduction at Thr-192 3 Cys, 8-fold reduction at Ala-196 3 Cys). The affinity of formylcholine, which lacks the terminal methyl group of ACh, showed less than a 3-fold change in response to Cys mutations of , and less than a 2-fold reduction on making the corresponding Ala or Gly substitutions (Table 2 ). The affinity of the oxadiazole agonist L-698,583 was reduced only 3-fold by the Thr-192 3 Cys mutation, and this compound was not investigated further.
Effects on the PI Response
ACh elicits a robust PI response from COS-7 cells transfected with wild-type M 1 mAChRs, with an EC 50 value of 0.1 M, and an E max value equivalent to three times the basal activity. The effects of the TMD 5 mutations on the AChinduced PI response mediated by the M 1 mAChR were parallel to their effects on the binding of the agonist (Fig. 1b) . Significant reductions in ACh potency resulted from mutations of . Decreases also followed from the mutations of . As in the case of ACh binding, the effects of the Cys mutations were generally similar to those of the other mutations made at these sequence positions; replacement of Ala-196 by Gly had a somewhat larger effect than replacement by Cys. The maximum responses elicited by the mutant receptors were similar to wild-type (Fig. 1b) . Calculations of signaling efficacy were performed as described previously (Hulme and Lu, 1998; Lu and Hulme, 1999; Ward et al., 1999) . These assess the effects of mutations on the functional potency relative to the binding affinity, taking into account changes in receptor expression level. They showed a 3-fold decrease relative to wild-type for Thr-192 3 Ala, and a 6-fold decrease for Ala-196 3 Gly (Fig.  1b) .
The mutation Phe-190 3 Cys resulted in a 10-fold increase in ACh potency, again in parallel to the binding assay (Fig.  2b) . Calculation of the signaling efficacy suggested a 4-fold increase relative to the wild-type receptor. This mutation also significantly increased the agonist-independent activity of the receptor, to 17% of the total signal. The enhanced basal activity could be consistently inhibited by preincubation of the cells for 24 h with the muscarinic antagonists atropine and NMS (Fig. 2c) , as reported for other constitutively active mutants . The maximum PI response elicited by the partial agonist pilocarpine was also significantly increased from 72% of the maximal ACh response in the case of the wild-type receptor to 96% of the response for the Phe-190 3 Cys mutant (Fig. 2d) . The Phe-190 3 Ala mutant did not exhibit raised basal activity.
Blockade by Sulfhydryl Reagents
BrACh. BrACh is a sulfhydryl-alkylating derivative of ACh. The ionization constants of most protein thiols are between 8 and 10. BrACh reacts with the thiolate anion, so reactions with BrACh were carried out at pH 8.0 in an attempt to ensure the ionization of a significant fraction of the sulfhydryl (SH) groups under conditions compatible with the stability of the M 1 mAChR. Preliminary experiments showed that BrACh reacts efficiently and stoichiometrically with Cys SH groups under these conditions with a rate constant of approximately 35 M Ϫ1 min Ϫ1 (Page, 1995) , a figure which is similar to its rate of reaction with ␤-mercaptoethanol (Damle et al., 1978) .
BrACh undergoes hydrolysis to bromoacetate and choline in aqueous solution. To try to assess the effect of this, the time course of BrACh inhibition of the binding of [ 3 H]NMS to wild-type M 1 mAChRs was measured at pH 8.0, and a comparison was made with ACh (Fig. 3a) . Binding of [ 3 H]NMS in the presence of ACh was near to equilibrium after 15 min. A 3-fold higher concentration of BrACh gave similar levels of inhibition at 10 to 15 min, but after an incipient plateau, the degree of inhibition by BrACh steadily diminished. Thus, 1 mM BrACh gave 90% inhibition of the binding of 0.3 nM [ 3 H]NMS at 15 min, but this was reduced to 25 to 40% at 2 h. The time-dependent reduction in potency is probably attributable to the hydrolysis of BrACh to bromoacetate and cho- line. Choline has an affinity of 10 3 M Ϫ1 for the M 1 mAChR (Page, 1995) (Table 3) .
The time-dependent hydrolysis of BrACh at pH 8.0 and 30°C to relatively inactive products was exploited to screen for irreversible reaction, by measuring the time-dependent reversal of the inhibition of To examine the concentration dependence of BrACh blockade of Thr-192 3 Cys receptors, membrane preparations were incubated with different concentrations of BrACh using a concentration of the membrane fraction 10 times that normally used in binding assays. After 15 min, the membranes were rapidly cooled to 0°C, diluted 10-fold with ice-cold binding buffer, and incubated for 2 h at 30°C with a receptorsaturating concentration of In an attempt to increase the extent of the block of Thr-192 3 Cys, two successive additions of 1 mM BrACh were made, each being incubated for 15 min. Blockade increased to 72% with little additional effect on the wild-type receptor (data not shown). Thus, the main factor limiting the rate and extent of block is likely to be the relatively rapid hydrolysis of BrACh at pH 8.0. Saturation binding curves were measured for membranes that had been pretreated with 1 mM BrACh for 15 min, diluted 20-fold with ice-cold binding buffer, centrifuged to To assess ligand protection of the blockade reaction, Thr-192 3 Cys membranes were pretreated for 10 min with a range of concentrations of NMS (0.1-100 nM) before exposure to BrACh (1 mM) for 15 min, and assay of the extent of blockade by incubation with a receptor-saturating concentration of [ 3 H]NMS for 2 h. NMS pretreatment reduced the extent of BrACh block from 48 Ϯ 2% to 12 Ϯ 0.2% (75% protection), with an IC 50 of 1 nM, a value consistent with the establishment of a reversible competitive interaction between NMS and BrACh before reaction. However, NMS, at concentrations up to 10 nM, did not appreciably affect the small degree of inhibition of Ala-193 3 Cys by BrACh. This may reflect the reduced affinity of this mutant for NMS (Table 1) , which may lead to less effective competition.
A concentration of 1 mM BrACh was used to quantitate the relative reactivities of the different mutants. This was sufficient to give an initial reversible occupancy in excess of 90% in each case (Table 3) . A 10-min incubation was used to attempt to restrict the reaction to the initial part of the blockade time course. The results are summarized in Fig. 5 .
A 10-min incubation led to 37% block of the binding of [ 3 H]NMS to Thr-192 3 Cys and 23% block of Ala-193 3 Cys. Blockade of the wild-type receptor, and of the other Cys substitution mutants was about 10%.
The introduction of bulky substituents into the side chain of ACh is known to reduce its efficacy. It was therefore of interest to investigate the properties of BrACh as an agonist. BrACh acted as a weak partial agonist with respect to the PI response elicited by the wild-type M 1 mAChR expressed in COS-7 cells (Fig. 6) , with an EC 50 value of 50 M, and a maximum response of 30% of the wild-type value. BrACh did not activate the Thr-192 3 Cys mutant (Fig. 6 ). Concentrations of BrACh higher than 3 mM caused nonspecific activation of the PI pathway in COS-7 cells (data not shown). Experiments in which cells expressing wild-type and mutant receptors were preincubated with BrACh have so far failed to give any evidence for irreversible stimulation of the PI signal.
Methanethiosulfonate Reagents and Iodoacetamide. Additional studies were made using methanethiosulfonate reagents, which have previously been applied to investigations of Cys substitution mutants of the D 2 dopamine receptor (Javitch et al., 1995) and the ␣ 2 -adrenergic receptor (Marjamä ki et al., 1998 (Marjamä ki et al., , 1999 . In addition, experiments were performed with the class-specific reagent, iodoacetamide.
Iodoacetamide failed to block the binding of either the wild-type or the Thr-192 3 Cys mutant receptor at concentrations up to 10 mM. Similarly, the negatively charged MTSES did not react with the wild-type receptor, or with the Thr-192 3 Cys mutant. In contrast, the tertiary amine, MTSEA (0.1 mM) blocked the binding site of the wild-type receptor, and unlike BrACh, must react rapidly with a Cys residue intrinsic to the wild-type receptor. These reagents were not investigated further.
MTSET, which, like BrACh, has a quaternary ammonium headgroup, showed greater selectivity (Fig. 7) . Using a 10-min incubation, 0.1 mM MTSET gave less than 20% block of the wild-type receptor but over 70% block of Thr-192 3 Cys and Ala-193 3 Cys. Unlike BrACh, it also showed evidence of reaction with Phe-190 3 Cys but not with the other Cys mutants. This pattern was maintained at 0.3 and 1 mM MTSET (Fig. 7 and data not shown) (Table 1) .
Discussion
The stretch of nine residues in TMD 5 of the M 1 mAChR examined in this study contains the threonine residues postulated to hydrogen bond to the ACh side chain (Wess et al., 1991 (Wess et al., , 1992 Wess, 1996) , and the alanine residues homologous to the catechol-binding serine residues in the catecholamine receptors. These residues have been replaced by cysteines, to allow reaction with sulfhydryl reagents, and by smaller amino acids, to probe the functional importance of each side chain.
The mutations had small effects on receptor expression levels, suggesting that none of the target amino acid side chains make intramolecular contacts crucial for the stability of the structure. The largest effect on the binding affinity of the antagonist [ 3 H]NMS was a 3-fold reduction resulting from mutation of to Cys or Gly. Thus, blockade of [ 3 H]NMS binding could be used to monitor the reaction of the Cys-substituted mutants with methanethiosulfonate reagents.
Reactivity with these polar reagents has been used to define the accessibility of residues from within the aqueous binding cleft of the D 2 dopamine and the ␣ 2A receptors (Javitch et al., 1995; Marjamä ki et al., 1998) . In the D 2 receptor, this required the substitution of Cys-118 in TMD 3, which otherwise reacts rapidly, blocking the binding site. There is no corresponding Cys in TMD 3 of the mAChR sequences. Accordingly, the quaternary ligand MTSET, and the negatively charged analog MTSES did not react rapidly with the binding site of the wild-type M 1 mAChR at concentrations up to 1 mM. The tertiary amine ligand MTSEA, Fig. 6 . Activation of wild-type and T192C M 1 mAChRs by BrACh. The PI response to BrACh was determined as described under Experimental Procedures, using a 30-min incubation. (F) ACh, wild-type; (E) BrACh, wild-type; (‚) BrACh, Thr-192 3 Cys. The pEC 50 value for BrACh activation of the wild-type receptor was 4.38 Ϯ 0.16 (n ϭ 3), and the E max value was 30 Ϯ 6% of the wild-type value for ACh. Points are mean Ϯ S.E. of triplicate measurements from a representative experiment. MTSET has a quaternary ammonium headgroup potentially capable of binding to , and Tyr-381 (TMD 6), which are thought to be important for ligating ACh itself (Spalding et al., 1994; Page et al., 1995; Hulme et al., 1999; Lu and Hulme, 1999; Ward et al., 1999) . This may explain its highly selective blockade of the Cyssubstituted M 1 mAChR mutants. MTSET reacted strongly with mutant receptors in which Cys residues were substituted for and . In the Baldwin model of the transmembrane region of the 7-transmembrane receptors (Baldwin et al., 1997) , these residues are positioned at the same level in the receptor structure as , which showed a slightly lower susceptibility, occurs one helical turn higher up. The effective protection of these residues against reaction with MTSET by the antagonist NMS suggests that they form part of the face of TMD 5, which is accessible from the binding cleft in the ground state of the receptor. This agrees with the orientation of TMD 5 proposed in the Baldwin model (Fig. 8a) . These findings resemble the observations of Marjamä ki et al., (1999) on the ␣ 2 -adrenergic receptor, but differ from the pattern of reactivity found in the Cys-118 3 Ser D 2 receptor (Javitch et al., 1995) , which suggested a strand rather than a helical conformation for the homologous sequence.
Mutations of four amino acids, 5.39, 5.42, and 5.46 ) significantly reduced both the affinity of ACh and the potency of ACh in activating the receptor. The effects of mutating the residues to Cys, or to Ala or Gly, in the case of , were similar and the effects on binding and activity were also of similar magnitudes.
A calculation of the signal transduction efficacies of the mutants (Whaley et al., 1994; Lu and Hulme, 1999) , taking into account the variations in receptor expression levels, indicated greater than 3-fold reductions in efficacy for PI signaling for Thr-192 3 Ala and Ala-196 3 Gly, but no significant change for the corresponding Cys mutations (Fig.  1) . These residues therefore make a contribution to ACh affinity and efficacy. However, they may not be as important for transducing ACh binding into receptor activation as are certain other residues, for example, Tyr-106 and Tyr-381 . Interpreted in terms of a two-state model of receptor binding, may make interactions that help to anchor ACh in the binding site in the ground state of the receptor, which then undergo a modest enhancement in the activated state . The effect on PI signaling efficacy was smaller than that reported for the homologous mutations in the M 3 mAChR (Wess et al., 1992) . The Thr-192 3 Ala mutation has also been studied after expression in A9L cells (Huang et al., 1999) . Relatively modest reductions in the low-affinity binding of ACh and carbachol and of the potency and efficacy of carbachol in PI signaling were reported. Interestingly, in contrast to the situation found in COS-7 cells, a significant fraction of GTPsensitive high-affinity binding sites was detected, and these showed greater sensitivity to the effects of the Thr-192 3 Ala mutation. The contribution of Thr-192 to agonist binding may depend on the nature of the G-protein coupled to the receptor.
The mutations of , and Ala-196 had a similar but smaller effect on the binding of two other agonists, carbachol and oxotremorine-M. Their effects on the binding of formylcholine were very small. Because formylcholine lacks the terminal methyl group of ACh, this seems consistent with a contribution by these residues to a methylbinding pocket, which is important for anchoring the extremity of the side chain of ACh and closely related compounds. In contrast, the adjoining 5.43 position is important for activation of the D 2S receptor by dopamine (Wiens et al., 1998) , but not the M 1 mAChR by ACh.
Represented on a polar plot (Fig. 8b) , all of the residues whose mutation decreased ACh affinity are clustered within a single 90°sector, further supporting a helical conformation for this part of TMD 5. Positions 5.38, 5.42, and 5.46, whose mutation most inhibited ACh binding, are identical with those that perturbed the binding of the antagonist sulpiride to the D 2 receptor (Javitch et al., 1995) . In the context of the Baldwin model, the center of this patch of residues is offset to one side of the binding cleft, appearing skewed toward the lipid bilayer beyond TMD 4. Interestingly, position 5.40, whose mutation to Cys increased receptor signaling efficacy, and induced basal activity, is modeled at the other side of the binding cleft, at the interface with TMD 6. Rotations of TMD 6 are implicated in receptor activation (Gether et al., 1997; Javitch et al., 1997; Spalding et al., 1998) , and could be modified by the introduction of a polarizable SH group into the neighboring helix.
To establish more directly the potential of residues in this sequence to contact muscarinic ligands, we probed the Cys substitution mutants with the alkylating ACh analog, BrACh. BrACh was less reactive than MTSET. Nevertheless, it was even more selective, reacting primarily with Thr (Fig. 8c) . It is interesting that a Cys residue introduced at position 5.42 in the ␣ 2 -receptor was selectively modified by chloroethylclonidine relative to MT-SEA (Marjamä ki et al., 1999) .
The rate constant estimated for the BrACh reaction with Thr-192 3 Cys (greater than 150 M Ϫ1 s Ϫ1 ) was slower than that reported for its reaction with the reduced nicotinic receptor binding site (5000 M Ϫ1 s Ϫ1 ; Damle et al. 1978) . This may reflect the existence of alternative binding modes for the ligand, which become favored in the mutant receptor because of disruption of the primary binding interaction, as proposed previously for the binding of ACh analogs . This could have the effect of reducing the concentration of the reactive species, contributing to the lower rate of reaction with the mutated mAChR binding site relative to the nicotinic binding site, in which the primary binding interactions may be less affected by reduction of the disulfide bond.
Specific binding interactions between the ester moiety of ACh side chain and hydrogen bonding moieties, such as the hydroxyl group of Tyr-381 , may restrict the mobility of the side chain of BrACh within the binding site of the mutant receptor. These interactions are not available to MTSET. Both the selectivity of BrACh for the 3 Cys mutant and the attenuation of the effect of the Thr-192 3 Ala and Thr-192 3 Cys mutations by the alteration (carbachol) or deletion (formylcholine) of the terminal methyl group of ACh suggest that interactions between the ester methyl group of ACh and the methyl group of Thr-192 make a significant contribution to the binding of ACh. Neighboring residues such as may then complete a binding pocket for the ACh methyl group. The asymmetric location of this pocket with respect to the center of the accessible face of TMD 5 suggests the possibility that a rotation of TMD 5 may be needed to optimize the binding of ACh. An ACh-induced rotation of TMD 5 could contribute to the formation of the activated state of the receptor.
